Innate Pharma is a publicly traded company trading on NASDAQ, led by CEO Jonathan E. Dickinson.
No upcoming earnings scheduled for Innate Pharma
No earnings announcement scheduled
Past 10 earnings reports for Innate Pharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | FY 2025 | -$0.64Est: -$0.65 | +1.5% | $10.5MEst: $7.2M | +45.0% | — |
| Sep 17, 2025 | H1 2025 | -$0.28 | — | $5.5M | — | — |
| Mar 27, 2025 | FY 2024 | -$0.65 | — | $21.5M | — | — |
| Sep 12, 2024 | H1 2024 | -$0.34 | — | $13.3M | — | — |
| Mar 21, 2024 | FY 2023 | -$0.10 | — | $66.4M | — | — |
| Sep 14, 2023 | H1 2023 | $0.02 | — | $43.5M | — | — |
| Mar 23, 2023 | FY 2022 | -$0.75 | — | $58.9M | — | — |
| Sep 15, 2022 | H1 2022 | $0.09 | — | $49.9M | — | — |
| Mar 24, 2022 | FY 2021 | -$0.65 | — | $28.3M | — | — |
| Sep 15, 2021 | H1 2021 | -$0.36 | — | $18.9M | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.